Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of fezolinetant for menopausal vasomotor symptoms
2018-003528-35Phase 3Unknown
- Sponsor
- Astellas Pharma
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fezolinetant in vasomotor symptoms (3 arms), sponsored by Astellas Pharma. Primary endpoint: Co-primary efficacy endpoints. Status: unknown.
02
Drugs
fezolinetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on 2018-003528-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003528-35.